Brian Skorney
Stock Analyst at Baird
(3.44)
# 797
Out of 4,828 analysts
108
Total ratings
42.11%
Success rate
5.68%
Average return
Main Sectors:
Stocks Rated by Brian Skorney
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SLNO Soleno Therapeutics | Maintains: Outperform | $102 → $105 | $77.09 | +36.20% | 4 | May 8, 2025 | |
| BIIB Biogen | Maintains: Outperform | $300 → $255 | $119.52 | +113.35% | 17 | May 2, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Neutral | $652 → $587 | $544.87 | +7.73% | 15 | Apr 30, 2025 | |
| BHVN Biohaven | Maintains: Outperform | $60 → $57 | $20.72 | +175.10% | 3 | Apr 28, 2025 | |
| MIRM Mirum Pharmaceuticals | Maintains: Outperform | $50 → $55 | $45.43 | +21.07% | 5 | Feb 27, 2025 | |
| DYN Dyne Therapeutics | Initiates: Outperform | $46 | $11.73 | +292.16% | 1 | Dec 13, 2024 | |
| BNTC Benitec Biopharma | Initiates: Outperform | $30 | $14.00 | +114.29% | 1 | Dec 13, 2024 | |
| APLT Applied Therapeutics | Maintains: Outperform | $14 → $5 | $0.40 | +1,159.76% | 4 | Nov 29, 2024 | |
| ENTA Enanta Pharmaceuticals | Maintains: Outperform | $26 → $20 | $5.40 | +270.37% | 6 | Nov 26, 2024 | |
| SRPT Sarepta Therapeutics | Maintains: Outperform | $200 → $193 | $38.20 | +405.24% | 9 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $80 → $95 | $96.96 | -2.02% | 2 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $25 | $5.28 | +373.48% | 1 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $32 → $10 | $2.21 | +352.49% | 2 | Oct 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Underperform | $215 | $271.84 | -20.91% | 4 | Sep 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $157 → $180 | $118.66 | +51.69% | 4 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $28 | $2.92 | +858.90% | 1 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $52 → $62 | $33.06 | +87.54% | 4 | May 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $34 → $39 | $7.66 | +409.14% | 3 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $63 | $35.54 | +77.27% | 1 | Dec 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $280 → $325 | $432.25 | -24.81% | 14 | May 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $10 | $14.59 | -31.46% | 2 | Aug 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $270 | $2.26 | +11,862.25% | 1 | May 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $18 → $6 | $3.47 | +72.91% | 1 | Feb 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $600 → $300 | $2.14 | +13,920.00% | 3 | May 7, 2018 |
Soleno Therapeutics
May 8, 2025
Maintains: Outperform
Price Target: $102 → $105
Current: $77.09
Upside: +36.20%
Biogen
May 2, 2025
Maintains: Outperform
Price Target: $300 → $255
Current: $119.52
Upside: +113.35%
Regeneron Pharmaceuticals
Apr 30, 2025
Maintains: Neutral
Price Target: $652 → $587
Current: $544.87
Upside: +7.73%
Biohaven
Apr 28, 2025
Maintains: Outperform
Price Target: $60 → $57
Current: $20.72
Upside: +175.10%
Mirum Pharmaceuticals
Feb 27, 2025
Maintains: Outperform
Price Target: $50 → $55
Current: $45.43
Upside: +21.07%
Dyne Therapeutics
Dec 13, 2024
Initiates: Outperform
Price Target: $46
Current: $11.73
Upside: +292.16%
Benitec Biopharma
Dec 13, 2024
Initiates: Outperform
Price Target: $30
Current: $14.00
Upside: +114.29%
Applied Therapeutics
Nov 29, 2024
Maintains: Outperform
Price Target: $14 → $5
Current: $0.40
Upside: +1,159.76%
Enanta Pharmaceuticals
Nov 26, 2024
Maintains: Outperform
Price Target: $26 → $20
Current: $5.40
Upside: +270.37%
Sarepta Therapeutics
Nov 7, 2024
Maintains: Outperform
Price Target: $200 → $193
Current: $38.20
Upside: +405.24%
Nov 7, 2024
Maintains: Neutral
Price Target: $80 → $95
Current: $96.96
Upside: -2.02%
Oct 31, 2024
Initiates: Outperform
Price Target: $25
Current: $5.28
Upside: +373.48%
Oct 23, 2024
Maintains: Outperform
Price Target: $32 → $10
Current: $2.21
Upside: +352.49%
Sep 25, 2024
Reiterates: Underperform
Price Target: $215
Current: $271.84
Upside: -20.91%
Aug 2, 2024
Maintains: Outperform
Price Target: $157 → $180
Current: $118.66
Upside: +51.69%
Jun 13, 2024
Initiates: Outperform
Price Target: $28
Current: $2.92
Upside: +858.90%
May 23, 2024
Maintains: Outperform
Price Target: $52 → $62
Current: $33.06
Upside: +87.54%
Mar 6, 2024
Maintains: Outperform
Price Target: $34 → $39
Current: $7.66
Upside: +409.14%
Dec 8, 2023
Initiates: Outperform
Price Target: $63
Current: $35.54
Upside: +77.27%
May 2, 2023
Maintains: Neutral
Price Target: $280 → $325
Current: $432.25
Upside: -24.81%
Aug 3, 2021
Downgrades: Neutral
Price Target: $10
Current: $14.59
Upside: -31.46%
May 20, 2021
Initiates: Outperform
Price Target: $270
Current: $2.26
Upside: +11,862.25%
Feb 26, 2021
Downgrades: Neutral
Price Target: $18 → $6
Current: $3.47
Upside: +72.91%
May 7, 2018
Maintains: Outperform
Price Target: $600 → $300
Current: $2.14
Upside: +13,920.00%